WELCOME TO

HealthInvest

September 2025

Cogstate (25 YEARS) · CLEVER CULTURE SYSTEMS · Tetratherix™ · Neurizon · EBR

PRESENTED BY: ir department... morgans

MEDIA PARTNER: STOCKHEAD

Your Co-Host

JANE LOWE

FOUNDER & MANAGING DIRECTOR

ir department...

Your Co-Host

SCOTT POWER

SENIOR ANALYST

morgans

#HealthInvest

HealthInvest September 2025

HealthInvest September 2025

#HealthInvest

Presenter

BRENT BARNES

CEO AND MANAGING DIRECTOR

CLEVER CULTURE SYSTEMS

ASX: CC5

AI-powered microbiology

Revolutionising microbial quality control in pharmaceutical manufacturing

Brent Barnes, CEO and Managing Director
September 2025



CLEVER CULTURE SYSTEMS

Disclaimer

This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct.

Given these uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, risk and uncertainties including, without limitation, risks associated with estimating potential quantity and timing of sales, risks associated with medical device development and manufacture, risks inherent in the extensive regulatory approval processes mandated by regulatory authorities, delays in clinical trials, future capital needs, general economic uncertainly and other risks detailed from time to time in the Company's announcements to the ASX.

Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

All reasonable efforts have been made to provide accurate information, but the Company does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect events or circumstances after the date of this presentation, except as may be required under applicable laws. Recipients should make their own enquiries in relation to any investment decisions from a licensed investment advisor.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

CLEVER CULTURE SYSTEMS

Problem

Millions of culture plates are manually read and reported annually during pharmaceutical manufacturing

Incorrect results costly

High cost of failure

Up to US$1bn lost revenue[1]

Failed results in pharmaceutical manufacturing can lead to substantial revenue losses. Catastrophic impact is patient death

Regulatory scrutiny

116% regulatory increase[2]

Rise in regulatory observations to drug establishments creates compliance challenges

Inefficient

Up to 98% zero growth plates[3]

Millions of plates reviewed annually, majority of plates have no growth yet require dual analyst verification, wasting resources

1. www.researchandmarkets.com, Global Pharmarcetuicals Market Report 2021: Covid-19 Impact and Recovery to 2030.
2. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
3. https://www.cleverculturesystems.com/scientific-library/apas-pharmaqc-ai-culture-plate-reading

Environmental monitoring today

Mandatory process in every pharmaceutical manufacturing facility globally

Culture plates

Environmental monitoring

Cleanrooms
(pharmaceutical manufacturing)

Incubation (3-7 days)

Critical decision point

Culture plate reading, reporting. Result to release pharmaceutical product

No Growth
➔ Batch release

Growth detected
➔ Batch held
➔ Investigation

Digital disruption

APAS INDEPENDENCE



Solution: APAS

Automated Plate Assessment System

Cutting edge AI technology
Machine learning for microbiology applications

Demonstrated performance
Extensive scientific data, faster than microbiologist

Improved data integrity
Automatic data trails and audit reports

Easy integration and user operation
Simple plug and play technology

Up to AU$1.5m revenue per APAS Independence sale[1]

Includes up-front Capex and Annual Recurring Revenue (ARR) streams

Product / Service	Description	Revenue Model	Approx. Split
APAS® Independence	Laboratory Instrumentation	Upfront Capex *(inc. financing options)*	40%
APAS Apps®	AI Software Licence	ARR	40%
APAS Service[2]	Support and maintenance services	ARR	15%
Implementation Services	Instrument connectivity, technical data and validation support	One-off	5%

1. Typical revenue over 7 years (expected life of instrument)
2. Third-party service provider / distributor expected to provide service

Opportunity

Clever Culture Systems.

AU$2.8B TAM

Total Addressable Market for aseptic manufacturing microbiology testing. Pharma companies are investing in expanding manufacturing facilities and automation

14 of Top 20

Sales pipeline includes largest pharmaceutical manufacturers globally. Opportunity for multi-instrument sales, establishes industry credibility.

>40 qualified leads

Sales momentum building. Qualified opportunities represent **~$75 million** in upfront sales and **$15 million** per annum in recurring revenues.

ASX: CC5



Market leader

- APAS Independence validated culture plate reading technology
- First and only end-point reader deployed in routine drug manufacturing

Growing customer base with top-tier pharma

- Customers include AstraZeneca, Pfizer, Novo Nordisk, Bristol Myers Squibb, Thermo Fisher
- Established sales pipeline >40 qualified leads representing $75m upfront capex + $15m ARR
- AstraZeneca land and expand case study, 9 sales completed across 8 global manufacturing sites

Financial stability

- Product sales transition Company to profitability
- Growing installed base builds platform for ARR growth

HealthInvest September 2025

#HealthInvest

Presenter

WILL KNOX

CEO AND EXECUTIVE DIRECTOR

Tetratherix™


ASX:TTX
Material science for safer, faster and more precise medicine
Tetratherix™
#anchoredbyscience

Tetratherix™

Why does the world need Tetratherix?

The evolving dynamics of the global healthcare system is demanding innovative and cost-effective biomaterials

Trends in healthcare delivery	How does Tetramatrix address the problem?
Rising patient expectations Patients are demanding increasingly higher quality of care, with a particular focus on **reducing recovery times** and **lowering risk of complications** (e.g. infection, blood loss, pain) - which is also a driver of increasing healthcare costs for patients and payers.	**Minimally invasive delivery** Water-based solution injected through fine gauge needle **Safe, biocompatible and bioresorbable** No foreign body reaction upon application
Need for cost-effective, decentralised care Increasing global healthcare spending and demand for healthcare services is necessitating investment in **cost-effective tools and treatments**, including those that can be **delivered outside a traditional hospital setting**, to minimise burden on the healthcare system	**Low cost, scalable production** Non-labour intensive, low cost and readily available materials **Seamlessly integrated into existing workflows** Delivered via needle with no additional equipment required

Tetratherix™

An operational moat with IP Leadership built on a global R&D infrastructure. This sets us apart.



bsi.

Supported by complete IP coverage

Patent stack with 36 granted patents from 9 families of patent, extending to 2044 & beyond and fully owned by Tetratherix

1 Lean & rapid R&D

Multiple independent research partnerships help us develop technologies faster and cheaper than our peers

2 Robust Quality System

We built a quality system from the ground up deliberately from day 1 - not just a science experiment

3 Strategic Patent Library

Our approach to patent coverage is optimised for future growth



Total Underlying Expenditure

*R&D includes specific projects, directly attributable staff, laboratory costs, trademarks and patents

Tetratherix™

Tetramatrix™ – A proven material platform that provides differentiation across multiple indications

An entirely new range of chemical entities that are built on a platform with deliberate conviction

3 New chemistries from a single Platform

PNPHO

PPHO

PH2NO

3

Technical and translational offering

Minimally Invasive



Low cost & scaled manufacturing

5

Products under development

- Three clinical trials
- 3 confirmed partnerships

Tetratherix™

Tetramatrix™ platform technology is the world's first biostealth fluid matrix

Intelligent

A decade of polymer programming has led to an ideal consistency & physical performance. The material is an injectable fluid to avoid causing damage to the body during its application. Using physiological temperature, material transitions into a 3D matrix.



Modular

A biomaterial platform built with unique polymer programming akin to "medical Lego® " to form implantable products to solve a wide range of clinical problems. The platform has built products for 7 anatomical sites with 3 chemical entities derived from the core technology.



Biomimetic

The matrix has similar water content and mechanical properties to natural tissue, and therefore is impervious to the body, helping heal injuries or physically manipulating the body during surgical interventions.



Safe

Due to the unique polymer programming of the material, once the matrix serves its purpose, the material gradually and safely bioresorbs in the body with no impact locally or systemically. Biocompatibility data from multiple clinical trials show no impact to internal organs or blood markers.

Preclinical studies (equivalent to 5 litre product administration)

- ✓ No effects on blood markers for internal functions of liver, kidney and spleen
- ✓ Fully resorbed and excreted from the body

Tetratherix™

Derived products from the Tetramatrix™ platform technology span 3 large franchises and significant near-term commercial opportunities

Bone Regeneration

Flowable bone graft extender for orthopaedic applications



Bone graft extender for dental surgeries

Tissue Spacing

Spacer during cataract surgeries



Prostate Spacer for radiation therapy



Tissue Healing

Intraoperative solution to reduce scar formation after surgeries







Same core technology, same material and interchangeable dataset

95%

FDA

Tetratherix™

15 years and 14 programs have helped define 5 initial products on the Tetramatrix™ platform technology



An initial addressable combined market of $USD6.8B



Tetratherix™

Different clinical needs. Different market segments. Single Tetramatrix™ platform technology.



Same core technology, same material and interchangeable dataset

Think of us like a software platform business...

The Tetramatrix biomaterial is our **core 'platform' technology**. We have completed the foundational safety, efficacy and manufacturing work which is transferable across different clinical applications of the platform.

We will **license the IP** in a specific field to a leader in the segment. These partners complete the "final 20%" to turn the application into a clinical product. We will then manufacture the product and supply at attractive unit economics to our industry leading partners who distribute it though their sales channels.

We will enjoy periodic milestone payments as well as a steady flow of income from product supply - a dual revenue source brings the best of both worlds.



Advanced manufacturing and operations

We have established advanced manufacturing in Sydney. To meet growing demand, a new lease agreement has been executed and the new facility is planned to be commissioned in 2026, with a modular design to allow us to quickly scale as needed.

Our manufacturing process is:

Highly Scalable with supply chain security

- Our manufacturing process is design in a 'POD' framework whereby every POD can operate independently
- The POD has a foot print of 200 sqm, and can be replicated multiple times without our facility floorspace
- Allows multiple X increases in the production capacity in a fast and controlled manner

De-risked

- We have previously increased our production yield per batch from laboratory scale (10 g per batch) to a commercial scale (1.2kg) through multiple cycles of process optimisation and scale up
- The production process is not labour-intensive and requires only off-the-shelf equipment
- All raw materials are catalogue products and easily accessible from multiple suppliers, de-risking any supply chain risk
- A new, larger site in Alexandria, Sydney has been identified **with the lease now executed and signed**

Manufacturing POD

A partnership model built on long term trust & deliberate pathway to market

Our Partnership model

STAGE 1
Proof of Concept

Tetratherix

Tetratherix uses foundational Tetramatrix™ data to conduct proof-of-concept and pilot trials, aligning endpoints and assessments with partners throughout the process

STAGE 2
Transition to Market

PARTNER

Tetratherix and its partner co-develop regulatory, reimbursement and launch strategies. Alignment on product form, branding and short-term manufacturing underpins regulatory submission and market entry

STAGE 3
In Market

PARTNER

With medtech launch experience, the partner will design a roll-out strategy focused on key regions and clinical marketing to ensure a steady, sustainable market entry

A true ‘win-win’ for TTX and its partners

Staged partnership built on tight collaboration that will limit risk and build long-term sustainability

Reducing Risk with Diversified Franchises

By having multiple shots on goal across a range of market and partner opportunities, we reduce the regulatory, technical and commercial risk inherent to our peers in the medical technology industry.

Faster Path to Free Cash Flow for TTX

We deliberately utilise our partners’ global infrastructure for sales and distribution. This creates a capital-light cost structure upon which sits rapidly compounding revenue.

Enabling Cost-Effective R&D for Partners

Early integration of the TetramatrixTM platform technology into partners’ internal development programs reduces their R&D inertia and reliance on late-stage M&A to meet their customers’ needs.

Tetratherix™

A capital light model with compounding revenue

While we build our own production and R&D infrastructure, we avoid committing capital on establishing multiple sales & distribution networks by utilising the capabilities of our partners' established teams.

Importantly, we operate in unison with our partners. Our high margin revenue compounds over time by adding new partnerships and launching new products.

Similar to a 'build-to-buy' model, we partner differently to, and at earlier stages than, traditional medtech companies. Therefore, our return profile is different and not built on expectations of an eventual acquisition.

"Tetratherix is software platform thinking applied to the vast opportunity for smart medicines. I'm excited about the many applications that can be delivered over time and the impact they will have to millions of people."

Rod Drury
Xero Founder & Tetratherix Investor



Tetratherix™

Not simply a science experiment. Tetramatrix™ provides real world economics.

	Bone Regeneration	Tissue Spacing	Tissue Healing
TAM	US$3.4bn	US$1.3bn	US$2.1bn
Payer	Patient out-of-pocket	Reimbursed (US)	Patient out-of-pocket
Expected GM[1] for Partner	70-80%	~80-90%	~70-80%
Expected GM for TTX	60-70%	~75-85%	~60-70%

We verify the final end user pricing and the gross margin targets for our strategic partners before progressing

1. Weighted Blended Gross Margin

Strategic Commercialisation built on decades of global launches. It's in our DNA.



1 Commercial Viability Assessment as a first step

We determine commercial reality of the program including unit economics, reimbursement, ASC vs Hospital program as well as gross margin splits for all stakeholders. Not simply a great science experiment.

2 Partnership Confirmation after many years of diligence

We ensure our partner of choice is motivated, aligned and the right choice on the ground. Focus of strategic portfolio not only now but over the next 5+ years. This can take time but its worth it.

3 US Seeding Program following 510k clearance

Our products have to introduced into the market effectively to ensure sustainable and effective long term growth. This includes careful selection of a small number of US tier 1 key opinion leaders (KOLs) who provide clinical feedback and controlled usage in early stages of US launch.

4 US Market Expansion (P2P)

Following a 1-2 year seeding period, we work with our selected partner to expand into tier 2 KOLs via careful peer-to-peer education & marketing with inclusion of messaging tips and advice from seeding KOLs. Organic US growth follows.

5 Geographical Expansion on the back of refining innovation uptake

With US tier 1 and tier 2 usage under our belts, we utilise this loyal and leading group of physicians to collect US data for CE mark, Asia and Sth American expansion - with these markets adopting our seeding approach where suitable.

Near Term Milestones

Tetratherix™

Tetratherix™

Relentless execution with regular newsflow in first 12 months post-listing

Bone Regeneration

Tissue Spacing

Tissue Healing

DENTAL		**Henry Schein Supply and Licensing Agreement Execution**	Data Read-out from the FDA study	FDA Submission	**FDA Clearance**
ORTHOPAEDIC		Master Partnership Agreement Execution	**Supply and Licensing Agreement Execution**	FDA Submission	**FDA Clearance**
ONCOLOGY	FDA Pre-submission/ Regulatory Pathway Defined	**Tutelix First In Human Cohort 1 Read-out**	Quality Agreement Execution	US/AU Capital Raise	**Tutelix Primary End Point for Cohort 2**	**US Clinical Trial Initiation**
OPHTHALMIC	**BioOptix Licensing Agreement**	Strategic Global Partnership	US / AU Capital Raise	Preclinical Data Read-out	**FDA Pre-submission & Regulatory Pathway**
SURGICAL SITE MGMT	Cohort 2 Commenced	**Year 1 Follow up for Cohort 1 results published**	Primary End-point Cohort 2	**FDA Pre-submission & Regulatory Pathway**	TetraDerm Cohort 3 Initiation (Major Surgeries)

FY2026

FY2027

#anchoredbyscience



Copyright Tetratherix Ltd. 2025 “Tetratherix”

HealthInvest September 2025

#HealthInvest

Presenter

DR MICHAEL THURN

CEO & MANAGING DIRECTOR

Neurizon

Neurizon

Shaping the future of neurodegenerative diseases

HealthInvest

24 September 2025

ASX: NUZ

Disclaimer

This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the "Company")). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company.
The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

Our vision is to lead the development of neurodegenerative treatments towards a promising new horizon for patients.
Neurizon

Corporate Overview

Mid-stage biotechnology company targeting human neurodegenerative diseases

Share Price Performance



Capital Structure (AUD$)

	9 September 2025
Current Share Price (NUZ/NUZOA)	$0.145/ $0.055
52 Week Low / High (NUZ)	$0. 096/ $0.24
No. of Shares (NUZ)	492,305,766
Listed Options (NUZOA)	116,315,955
Market Capitalisation	**$71.38m**
Cash (as at 30-Jun-25)	$4.16m
Debt (as at 30-Jun-25)[1]	Nil
Net Cash	**$4.16m**
Enterprise Value	**$67.22m**
Unlisted Options (10c/15c/17.5c/20c/26c/33.25c)	27.03m
Enterprise Value (fully diluted)	**$88.01m**

Board & Management

Mr Sergio Duchini	Chairman & Non-Executive Director
Dr Michael Thurn	Chief Executive Officer & Managing Director
Mr Marcus Hughes	Non-Executive Director
Dr Katie MacFarlane	Non-Executive Director
Mr Dan O'Connell	Chief Financial Officer
Mr Stefan Ross	Company Secretary

Top Shareholders (as at 9 September 2025)

Hybrid Holdings Pty Ltd <Darcy Family Super Fund A/C>	4.52%
Mr GJ & Mrs G Van Blommestein <Van Blommestein S/F A/C>	3.78%
Dr Roger Aston	3.06%
Mr Chek Loon Tan	2.70%
Board & Management	4.03%

[1] Excludes A$1.5m R&D refund loan provided by Radium Capital taken out after 30 June 2025, secured against a small portion of the expected 2025 R&D Tax Rebate

From Humble Beginnings

Scientific reappraisal of an approved veterinary product uncovered a new pharmacology for neurodegenerative disease



Monepantel

Unique pharmacology specific to nematodes worms

Antihelminth

Approved Veterinary Product

2005

Anticancer

Active against a range of cancer cell lines

2011

Autophagy Activator

mTOR pathway signature

2013

NUZ-001

Phase 1 ALS POC

Method of use patents expiring 2041

2024

Potential Platform Therapy

for Neurodegenerative Diseases

2025

Elanco

- **2009:** First approved in **New Zealand** for sheep, marketed as **Zolvix®**
- Soon after, approved in **Australia, the EU, and other regions** as the **first new broad-spectrum anthelmintic class in 25+ years**

Neurizon

- **2011:** Anticancer activity identified in multiple cancer cell types
- **Autophagy:** A lysosome-dependent process that clears unnecessary or toxic cellular components

- **Monepantel (NUZ-001)** has undergone rigorous animal testing comparable to human drug safety requirements
- **Leveraging these existing data** and safety profiles can **save time, reduce costs, create novel therapeutic opportunities, and enable faster, safer routes to market**

NUZ-001: A Platform Molecule for Proteinopathy-Driven Diseases

Impaired proteostasis contributes to intracellular inclusion bodies of misfolded proteins is a hallmark of neurodegenerative diseases

TDP-43
ALS/AD/PD/FTD/CTE

Amyloid beta
AD/PD

Tau
AD/PD/FTD/CTE/PSP

alpha Synuclein
AD/PD

mHTT
HD











NUZ-001 represents a mechanism-driven, disease-agnostic approach to treating neurodegeneration by rebalancing proteostasis and reversing core cellular dysfunction

AD = Alzheimer's Disease; ALS = Amyotrophic Lateral Sclerosis; CTE = Chronic Traumatic Encephalopathy; FTD = Frontotemporal Dementia; HD = Huntington Disease; PD = Parkinson's Disease; PSP = Progressive Supranuclear Palsy

Our Strategic Progress

Initial focus is on advancing clinical work on ALS, following acceptance into the HEALEY ALS Platform Trial

Partnerships & Licensing	Drug / Dosage Form	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Approved/ Marketed	Next Major Catalysts
Elanco Licensing Agreement	HEALEY ALS Platform Trial	NUZ-001 Oral Tablets	Amyotrophic Lateral Sclerosis (Motor Neurone Disease)	✓	✓	Pivotal registration adaptive Phase 2/3 clinical study HEALEY ALS Platform Trial	✓ Accelerated approval possible on Phase 2 data and enabled through Elanco licensing	• Regimen Specific Design • Open IND • HREC/IRB Approval • First Patient In
	Preclinical & research partners	NUZ-001 Oral Tablets or Liquid	Neurodegenerative DIseases	✓				• Identify Next Target Indication • Preclinical Data

Strongly Positioned with Regulatory and Commercialisation Requirements for Realisation

Access to animal safety data and manufacturing data critical to support future trials and potential regulatory approvals

Access to manufacturing at scale critical to future commercialisation

Derisked regulatory approval process

TDP-43 Aggregates are a Hallmark of ALS Pathology

Protein aggregates are cleared by multiple pathways including autophagy-lysosomal and ubiquitin-proteasome systems. Together these systems help to maintain proteostasis

ALS Patient Population[1]



Spinal Cord



Clearance of misfolded proteins in healthy motor neuron



NUZ-001 enhances autophagy to maintain proteostasis

FUS = Fused in Sarcoma; SOD1 = Superoxide Dismustase 1; TDP-43 = Transactive response DNA-binding protein 43

1. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013 Aug 7;79(3):416-38. doi: 10.1016/j.neuron.2013.07.033. PMID: 23931993; PMCID: PMC4411085.

Year in Reverse Highlights

From clinical and regulatory achievements to strategic partnerships and patient-focused innovations.

Inclusion in the HEALEY ALS Platform Trial

Lead asset, NUZ-001, selected for inclusion in the HEALEY ALS Platform Trial across +70 clinical sites in the US. Provides framework for independent validation of the potential of NUZ-001 as a treatment for ALS/MND and accelerates the path to FDA approval.

Completion of Phase 1 MEND and Open Label Extension Studies

The top line study results for 10-patient group - who all completed the earlier Phase 1 MEND Study – further demonstrate the long-term safety and efficacy signals of the treatment of ALS/MND with NUZ-001, building on interim findings that confirmed robust survival and functional benefits .

Grant of "Method of Use" Patent until 2041

Expedited grant of 'method of use' patent for NUZ-001 by the United States Patent & Trademark Office (USPTO). US patent protection for NUZ-001 and structurally related compounds for neurodegenerative diseases/cancer now extends to 2041.

Global Licence Agreement with Elanco

Exclusive global license agreement with Elanco Animal Health (NYSE:ELAN) for the rights to the active pharma ingredient in NUZ-001, aiding commercialisation pathway provides Neurizon with access to Elanco's comprehensive data set to support future regulatory submissions.

Development of Oral Liquid Formulation of NUZ-001

Successful development of a new oral liquid formulation of NUZ-001 for the treatment of ALS/MND, designed to support patients with all stages of ALS/MND, particularly those with swallowing. Developed as part of Neurizon's patient-centric innovation strategy, the liquid form enhances continuation of treatment, ease of administration, and overall treatment experience for patients with ALS.

Preclinical Advances Supporting Platform Potential

Preclinical studies strengthened the scientific foundation for NUZ-001 as a platform therapy beyond ALS/MND, demonstrating brain penetration, significant reduction of TDP-43 aggregation, restoration of neuronal survival factors, and protection against multiple pathways of neurodegeneration. These findings, showcased at leading international conferences, reinforce NUZ-001's potential to address a broad range of neurodegenerative diseases.

Together, we are moving closer to making treatments a reality for people living with ALS/MND and other neurodegenerative diseases.

Phase 1 ALS MEND and Open Label Extension (OLE) Study Design

The Phase 1 MEND Study was an open-label, multicentre study involving 12 patients with ALS that commenced in October 2022 and provided patients with ongoing access to NUZ-001 through a compassionate-use program and later a 12-month open-label extension study

Study Design



Study Update

- Positive Phase 1 MEND Study top-line results released in Q1 CY24
- 12 patients continued treatment with NUZ-001 under a compassionate-use program
- 10 patients rolled-over into a 12-month Open-Label Extension (OLE) Study. The final study patient completed the treatment period earlier this year
- Top-line results demonstrated long-term safety and efficacy signals of ALS treatment with NUZ-001
- NUZ-001 has been safely used for more than 2.5 years, with five patients still receiving treatment under the TGA's Special Access Scheme
- Phase 1 and baseline OLE data used to design pivotal registration adaptive Phase 2/3 Study, to commence in Q4 CY2025

Phase 1 Open Label Extension
Survival Probability Analysis

Compared to matched controls from the PRO-ACT, treatment with NUZ-001 results in a significantly (X^2=13.75, p=0.00021) longer survival of patients with ALS

Analysis Method		Log-Rank Test		Cox Proportional Hazards Model		
Dataset	Death Time Imputation	χ^2	p-value	Hazard Ratio	95% CI	p-value
Assumed Survival	Leave out	13.75	0.00021	0.233	(0.096, 0.566)	0.0013
	Last Visit	14.88	0.00011	0.225	(0.093, 0.544)	0.0009
Confirmed Survival	Leave out	20.87	0.00000	0.203	(0.087, 0.472)	0.0002
	Last Visit	22.79	0.00000	0.194	(0.083, 0.450)	0.0001



Hazard ratio of 0.233 (95% CI: (0.096, 0.566), p = 0.0013) indicating that treatment with NUZ-001 reduces the risk of death by 76.7%

Comparison of Key Outcomes Across Approved ALS Treatments & NUZ-001

Cross-trial comparisons are descriptive only; differences in study design, patient populations, and endpoints limit direct comparability.

			PRICE & SALES	ALSFRS-R (Improvement Compared to Placebo)	FVC/SVC (Improvement Compared to Placebo)	Survival (Improvement Compared to Placebo)	
01 (1995)	Riluzole[1] (Rilutek®)	52 weeks	List price US$5,360 ~US$40 mil in sales[11]	Not evaluated	Not evaluated	~3 months	n=77
02 (2017)	Edaravone[2] (Radicava®)	24 weeks	List price US$171,000 ~US$1 bn in sales[11]	**33.20%** (p=0.0013)	**23.43%** (FVC, p=0.0942)	~6 months	n=69
03 (2022)	Amx0035[3,4] (Relyvrio®)	24 weeks	List price US$158,000 >US$400 mil in sales[12]	**23.27%** (p=0.030)	**22.37%** (SVC, p=0.080)	~6.5 months[5]	n=89
04 (2023)	Tofersen[6] (Qalsody®)	28 weeks	List price US$199,200 ~US$33.4 mil in sales[13]	**14.74%** (p=0.970)	**35.59%** (SVC, p>0.05)	Not evaluated	n=72
Investigational	NUZ-001[7]	40 weeks[8] 116 weeks[9]	NA	**39%** (p=0.080)[10] **31%** (p=0.145)[10]	**48%** (SVC, p=0.058)[10] **41%** (SVC, p=0.078)[10]	~16 months[10]	n=12

[1] N Engl J Med. 1994 Mar 3;330(9):585–9; [2] Lancet Neurol 201716: 505-12; [3] N Engl J Med 2020; 383:919-30; [4] Voluntary removal from the market; [5] Muscle Nerve. 2021 Apr;63(4):31–39. [6] Engl J Med 2022:387:1099-110; [7] Neurizon data on file; [8] Median treatment period in Phase 1 MEND Study; [9] Median treatment period for combined Phase 1 MEND Study and OLE Study; [10] Comparison to matched untreated controls in PRO-ACT Database; [11] Research Reports World 2024; [12] BioPharma Dive, ALS Drug Development, September 30, 2025; [13] Biogen 2024 Annual Report; Verified Market Report 2025;

Near Term Milestones

Significant near-term news flow drive value and growth

✓Execute **License Agreement with Elanco**

✓Completion of PK studies to **lift NUZ-001's IND clinical hold**

✓Submit request to US FDA to **lift NUZ-001's IND clinical hold**

✓**First registration batch** of NUZ-001

✓Preliminary **R&D Funding received**

✓**Top-line results from OLE study**

✓**PACTALS** conference and presentation

- **US FDA lifts clinical hold**
- Additional **preclinical updates**
- **HEALEY submits NUZ-001 protocol amendment** to US FDA for Platform Trial
- Supply Agreement **executed with Elanco**

- HEALEY ALS Platform Trial– **Initiation of site start-up activities**
- **NEALS** Annual Conference Meeting
- HEALEY ALS Platform Trial - **Investigator Meeting**
- Australian **R&D Refund** (net of R&D funding)
- **Second and Third registration batches** of NUZ-001
- 36th **International Symposium on ALS/MND**
- Additional **preclinical updates**
- FDA **Fast Track Designation for NUZ-001**
- **EMA Scientific Advice** meeting
- HEALEY ALS Platform Trial – **First patient recruitment**

CY 2025

Q3

Q4

ONGOING EFFORTS

✓ **Work to broaden pipeline to other neurodegenerative diseases**

✓ **Partnership expansion opportunities with patient associations**

✓ **Targeted engagement with potential strategic partners**



THANK YOU

Registered Address:
Suite 2, 385 Bourke Street
Melbourne, VIC 3000 Australia

+61 (3) 9692 7222

enquiries@neurizon.com

Neurizon

HealthInvest September 2025

#HealthInvest

Presenter

JOHN MCCUTCHEON

CEO AND PRESIDENT

EBR

HealthInvest 2025

John McCutcheon
President and CEO
September 2025

Pillars of Success

Developer of the world's first and only leadless pacemaker for heart failure
Listed on ASX (symbol EBR) since 2021 and SEC registrant since 2024

Significant Growth Potential

Unique solution

WiSE System is complementary to other cardiac pacing devices and is the only leadless device that can pace the left ventricle for heart failure

Large market opportunity

Targeting an initial addressable market of US$3.6bn in the US

Barriers Removed

FDA approved

US FDA approval received 11 April 2025 supported by Breakthrough Device Designation and compelling clinical data

Strong reimbursement

Inpatient: CMS approved NTAP add-on payments commencing Oct 2025
Outpatient: CMS approved TPT pass through payments commencing Oct 2025

Poised to Scale

Clear commercial strategy

Pilot launch underway. Limited Market Release (LMR) to commence Q4 2025 to coincide with reimbursement add-on payments

Manufacturing facilities in place

New facility under construction to support commercial growth and scale

Expect full transition to new facility by the end of H1 2026

Cardiac Rhythm Management Market

Comprised of three key segments

Worldwide CRM Market (~US$13.6bn)[1]



- Cardiac Resynchronisation Therapy (CRT)
- Implantable Cardioverter Defibrillation (ICD)
- Pacemakers



(1) Cardiac Rhythm Market - Grand View Research

Leads – The Achilles' Heel of Cardiac Rhythm Management

Traditional CRT systems use wires or leads to deliver energy to the heart, which can lead to many problems.

Leads can migrate and fracture

Leads can become infected - a pathway for pathogens to reach the myocardium

Cannot be place inside (endocardially) the left ventricle



Left Ventricle (LV) lead must be placed outside the heart to avoid blood clots

Higher risk of complications with a lead-based upgrade to CRT

Risks increase as the number of leads increases

Market is Rapidly Adopting Leadless Devices as Standard

EBR's WiSE System is the only leadless device that can deliver leadless left ventricle pacing for cardiac resynchronisation therapy

WiSE System fills the gap

The only leadless solution for left ventricle (LV) endocardial pacing

Other wireless pacemakers are too big for LV pacing

Their size increases the risk of blood clots, restricting their use to right ventricle (RV) and right atrium (RA) pacing only

Complementary solution

WiSE System can be used in conjunction with leadless pacemakers to deliver totally leadless CRT

Strong competitive protection

WiSE System is protected by over 97 issued patents globally

Left ventricle[1]



EBR Systems
WiSE Electrode

Right ventricle / atrium[1]

Medtronic
Micra®

Boston
Scientific
Empower®

Abbott
Aveir®

Extravascular / Subcutaneous ICD[1]

Boston
Scientific
Emblem®

Medtronic
Aurora®

(1) Illustrative sizing (not to scale)

WiSE System for Heart Failure Patients

Designed to overcome the limitations of conventional lead-based CRT



Leadless

Ultra-compact device removes constraints of lead-based pacing systems

Versatile

Open platform synchronises with a range of existing pacing devices

LV Endocardial Pacing (LVEP)

Directly stimulates the heart's natural conduction system

Targeting a US$3.6bn Total Addressable Market

Total addressable market represents patients with limited or no other options



Upgrade of a leadless pacemaker with WiSE to provide totally leadless CRT

Total Addressable market (~US$3.6bn)[2]

Leadless Upgrades (~17K patients/yr)

- Patients with a leadless right ventricle pacemaker can only upgrade with WiSE CRT System to receive effective CRT
- WiSE CRT System paired with leadless pacemakers*

Rapidly growing segment

Acute Lead Failure (~11K patients/yr)

Unable to implant CRT wire in a new CRT patient.



High Risk Upgrades (~20K patients/yr)

Patient requiring CRT, but is deemed too high risk for a conventional CS lead placement

Chronic Lead Failure (~32K patients/yr)

Traditional CRT system implanted but has ceased to provide effective CRT

*Medtronic's Micra leadless pacemaker has been qualified for use with WiSE CRT.
Abbott's Aveir leadless pacemaker has not yet been qualified for use with WiSE CRT, but testing conducted by EBR is in progress.

(1) Cardiac Rhythm Market - Grand View Research;
(2) Grand View Research – Leadless Pacemakers Market, Cardiac Rhythm Market, Cardiac Resynchronization Therapy Market, WiSE current indications

Executing a Clear Commercialisation Strategy

Reimbursement provides significant tailwinds

- ✓ Inpatient New Technology Add-on Payments (NTAP[1]) approved by CMS commencing October 1, 2025
- ✓ Outpatient Transitional Pass-Through (TPT[1]) payments pending final ruling, expected to commence October 1, 2025
- ✓ First technology accepted into the Transitional Coverage for Emerging Technologies (TCET) program for transitional national coverage decision;

Disciplined approach to commercialisation, limiting execution risk

- ✓ First sales achieved in 2Q ‘25 during pilot phase
- ✓ Limited Market Release (LMR) beginning 4Q ‘25 coinciding with initiation of add-on and pass-through payments
- ✓ Focused subset of strategic hospitals to be targeted
- ✓ Significant support and advocacy from US physicians

Continued investment in expanding commercial leadership team and sales force

- ✓ Investment into leadership team including appointment of Chief Commercial Officer and 2 VPs of Sales and a VP of Marketing
- ✓ Direct sales force with 8 territories in place by year end 2025, each consisting of a sales rep and a clinical / technical specialist

(1) ASP: Average Selling Price, NTAP: New Technology Add-on Payment, TPT: Transitional Passthrough Payment;
(2) U.S. pricing with New Technology Add-on Payment (NTAP) post-approval

WiSE Reimbursement

As a new medical device, EBR's WiSE System has unprecedented access to reimbursement

Medicare In-patient Payment

New Technology Add-On Payment (NTAP)

- CMS has approved the NTAP payment for WiSE
- NTAP payments to commence October 2025
- Add-on payments based on US$63,300 ASP

Benefits of NTAP:

- Designed to cover the increased cost of important new technologies
- Reduced financial barriers for sites and improves access
- Validates the technology's innovation and clinical benefit

Medicare Out-patient Payment

Transitional Pass-Through (TPT) Payment

- CMS has approved WiSE TPT reimbursement up to US$63,300 ASP
- Commencing October 2025

Benefits of TPT:

- Covers cost of WiSE system
- Reduced financial barriers for sites and improves access
- External validation that the technology represents a meaningful clinical advancement

Medicare Coverage

Transitional Coverage of Emerging Technologies (TCET)

- WiSE is **first** technology to be accepted in the TCET program
- Developing Coverage with Evidence (CED) protocol

Benefits of TCET:

- Early CMS engagement for an efficient review process
- Transitional NCD for up to 5 years
- Expedited Medicare coverage

World Class Manufacturing Facility

EBR has secured a new state-of-the-art facility to support long-term commercial growth and scale

Significant Facility Expansion:

- New 11-year lease secured for 51,000 sq ft (4,751 sqm) facility
- Expansion of capability from critical manufacturing processes to manufacture of complete units
- Expands EBR's manufacturing capacity to accommodate future growth and demand for WiSE

Phased Financial Commitment:

- Rent payments deferred until January 2026
- Gradual space occupancy and rent scaling up annually to full occupancy by year four
- Landlord to finance approximately US$4m in tenant improvements

Timing:

- Facility upgrades and qualifications to be completed progressively over the next year, with full transition to the new facility expected in H1 2026

State-of-the-art facility in Santa Clara, California

For further information see ASX announcement '*EBR leases new facility to expand manufacturing capabilities'*, 28 January 2025

Major Milestones

Proven track record of achieving major clinical, regulatory, and reimbursement milestones



(1) Left Bundle Branch Area Pacing (LBBAP)

Summary

EBR is poised for success to deliver superior treatment for patients suffering from cardiac rhythm diseases

- Developer of the world's first and only leadless pacing system for heart failure
- EBR's WiSE® System has no direct competitors and is complementary to other pacemaker technologies
- FDA approved and reimbursement in place supporting attractive ASP
- Significant market opportunity with an initial addressable market of $3.6bn
- Disciplined commercialisation strategy in place focusing on high-volume sites in the US, minimising execution risk

Thank You

www.ebrsystemsinc.com

HealthInvest September 2025

#HealthInvest

Q&A

THANK YOU FOR JOINING

HealthInvest

September 2025

Cogstate · CLEVER CULTURE SYSTEMS · Tetratherix™ · Neurizon · EBR

PRESENTED BY: ir department... morgans

MEDIA PARTNER: STOCKHEAD